Figure 3From: DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE studyChanges in CD34 in the sitagliptin and voglibose groups. A. Circulating CD34 levels at 0 week and 12 weeks in the sitagliptin and voglibose groups. *P < 0.05 vs. 0 W, paired t-test. B. Change in CD34 from the baseline to the end of follow-up (ΔCD34). **P < 0.05, Student’s t-test.Back to article page